Wonder exists in every corner. It’s always there, but is often difficult to perceive. When we do finally become aware of some of the wonder that surrounds us it can be an emotional experience.
A paradigm shift such as Copernicus’ geocentric theory, or Einstein’s theory of relativity are two most beautiful examples of such an event.
In the case of cancer, the ultimate disorder, a phenomenon that cannot be explained by conventional science was discovered at Hirosaki University, Japan. From this discovery a unique method of cancer diagnosis was patented in Europe & Japan . The finding was such that cancer cells would take up fluorescently labelled L-glucose, that normal cells will neither take up nor utilize. This finding was a true surprise and foreshadows a paradigm shift. This discovery received the highest rating from the Japan Science and Technology Agency (JST) for Science and Technology Incubation Program in Advanced Regions in FY 2008-2010. Years of clinical research was then conducted, and was awarded with the highest rating by the Japan Agency for Medical Research and Development (AMED), in its Collaborative Research Based on Industrial Demand Program in FY 2011-16. As a result, it became apparent that L-glucose is the key that will transform our approach to the battle against cancer. Paralleling this groundbreaking science, a number of novel cancer diagnostic methods were developed and patented internationally .
Based on this discovery, ORBIO CORPORATIONwill develop and deploy unprecedented cancer diagnostics and therapeutics using L-glucose as a lead molecule, while combining knowledge of medicine, biology, chemistry and physics. Working together with scientists who are taking advantage of this new knowledge surrounding L-glucose, ORBIO will deliver a new method for controlling cancer.
 JP6019500, EP2703495B1.  US8986656B2, US9958450B2, US10288604B2, US10509041B2, US10001487B2, US10551387B2, US10921256B2, EP2325327B1, EP2905620B1, EP3130596B1, EP3199638B1, ZL201280015126.5, ZL201380050786.1, ZL201580030346.9, JP 5682881, JP 6327565, JP 6406715, JP 6566348, JP 6670503, JP 6721868.
Cancer control born from Surprise.
By bringing together the wisdom and findings of medicine, biology, chemistry, and physics, 、 we will provide a revolutionary method of controlling cancer that is far more in harmony with the patient’s mind and body than are conventional cancer treatments. We will bring about a paradigm shift in medical technology. ORBIO.
By further advancing the fifth cancer treatment for all types of cancer, ORBIO will continue to take on the challenge of bringing it to patients and their families suffering from cancer as soon as possible, until cancer becomes just a disease that can be cured without burden.
- Grand ambition
- Technology to give shape to innovation
- Humility, honesty and sincerity/li>
ORIGIN OF THE COMPANY NAME
Oncotherapy Reacted By Integrated Organometal
HISTORY AND LOCATION
|Feburary,2020||Moved the head office and organized the founding team
Creation-Core Kyoto Mikuruma,
448-5 Kajii-cho, Kamigyo-ku, Kyoto 602-0841, JAPAN
|COMPANY NAME||ORBIO CORPORATION|
|CAPITAL||54 million yen|
|BUSINESS ACTIVITIES||Research and development of cancer treatment technologies. Creation of diagnostic and therapeutic agents for cancer|
|HEADQUARTER||Creation Core Kyoto-Mikuruma, 448-5 Kajii-cho, Kamigyo-ku, Kyoto 602-0841, Japan|
|Hirosaki Univ. Lab.||
ORBIO-chaired Institute for Molecular Transport Study, Hirosaki University
5 Zaifu-cho Hirosaki Aomori, 036-8562, Japan